ProKidney (NASDAQ:PROK - Get Free Report) is expected to be announcing its Q1 2025 earnings results before the market opens on Friday, May 9th. Analysts expect ProKidney to post earnings of ($0.16) per share for the quarter.
ProKidney (NASDAQ:PROK - Get Free Report) last released its earnings results on Monday, March 17th. The company reported ($0.17) EPS for the quarter, missing analysts' consensus estimates of ($0.14) by ($0.03). The business had revenue of $0.08 million during the quarter. On average, analysts expect ProKidney to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.
ProKidney Stock Down 7.2 %
Shares of ProKidney stock traded down $0.05 during trading on Wednesday, hitting $0.64. 533,078 shares of the company were exchanged, compared to its average volume of 689,921. The stock has a market capitalization of $187.41 million, a price-to-earnings ratio of -1.16 and a beta of 1.50. The firm has a 50 day moving average price of $0.86 and a 200 day moving average price of $1.42. ProKidney has a fifty-two week low of $0.46 and a fifty-two week high of $4.44.
Insider Activity
In other news, insider Control Empresarial De Capital bought 100,000 shares of ProKidney stock in a transaction dated Wednesday, April 16th. The shares were acquired at an average cost of $0.75 per share, with a total value of $75,000.00. Following the completion of the transaction, the insider now owns 73,430,330 shares in the company, valued at approximately $55,072,747.50. This trade represents a 0.14 % increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders purchased 1,787,716 shares of company stock valued at $1,175,419 in the last ninety days. Company insiders own 41.49% of the company's stock.
About ProKidney
(
Get Free Report)
ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease.
Read More
Before you consider ProKidney, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ProKidney wasn't on the list.
While ProKidney currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
